:@0.085519:0.075583:0.090751:0.075583:0.090751:0.059604:0.085519:0.059604:0.005232
 :@0.621674:0.075583:0.626906:0.075583:0.626906:0.059604:0.621674:0.059604:0.005232
 :@0.884977:0.940183:0.890322:0.940183:0.890322:0.922163:0.884977:0.922163:0.005345
Oral Presenter Abstract :@0.736982:0.075583:0.918858:0.075583:0.918858:0.059604:0.736982:0.059604:0.011658:0.006331:0.008492:0.004000:0.005293:0.010369:0.006331:0.008929:0.008569:0.008929:0.009573:0.005251:0.008929:0.006382:0.005321:0.010407:0.009403:0.008511:0.005289:0.006275:0.008531:0.008531:0.005340:0.005232
OT-3 :@0.083238:0.078822:0.144017:0.078822:0.144017:0.060055:0.083238:0.060055:0.018387:0.014681:0.007982:0.013113:0.006617
The role of ROS generation in the anticancer activity of novel Schiff base :@0.112742:0.138154:0.893205:0.138154:0.893205:0.116169:0.112742:0.116169:0.013042:0.013433:0.013068:0.006573:0.008686:0.013094:0.006651:0.013146:0.006417:0.013042:0.007460:0.006521:0.015285:0.016041:0.014398:0.006599:0.013511:0.013068:0.013459:0.013068:0.008686:0.012703:0.007668:0.006651:0.013042:0.013355:0.006573:0.006651:0.013407:0.006521:0.007668:0.013433:0.013068:0.006521:0.012650:0.013355:0.007668:0.006729:0.011685:0.012650:0.013355:0.011894:0.013068:0.008686:0.006573:0.012650:0.011816:0.007668:0.006756:0.011711:0.006651:0.007668:0.011685:0.006573:0.013042:0.007460:0.006521:0.013407:0.013042:0.011711:0.013146:0.006547:0.006521:0.014398:0.011816:0.013407:0.006547:0.007381:0.007381:0.006521:0.013537:0.012650:0.011842:0.013068:0.006521
compound in triple-negative breast cancer  :@0.273280:0.162242:0.739940:0.162242:0.739940:0.140257:0.273280:0.140257:0.011816:0.013094:0.019641:0.013537:0.013042:0.013459:0.013355:0.013537:0.006573:0.006651:0.013355:0.006364:0.007668:0.008686:0.006703:0.013537:0.006651:0.013300:0.008694:0.013355:0.013120:0.013511:0.012650:0.007747:0.006651:0.011581:0.013068:0.006573:0.013485:0.008686:0.013146:0.012650:0.011842:0.007668:0.006573:0.011816:0.012650:0.013433:0.011685:0.013068:0.008686:0.006832:0.006521
Reyhaneh Farghadani*, Han Yin Lim, Mahmood Ameen Abdulla, Jayakumar :@0.144812:0.204636:0.861654:0.204636:0.861654:0.184574:0.144812:0.184574:0.013663:0.011211:0.010664:0.011901:0.010568:0.011925:0.011211:0.011901:0.006570:0.010902:0.010664:0.007950:0.011687:0.011901:0.010664:0.011901:0.010568:0.011925:0.005093:0.009426:0.005951:0.006427:0.014639:0.010592:0.011925:0.006570:0.013187:0.004808:0.011925:0.006570:0.011973:0.004856:0.018495:0.005951:0.006450:0.018590:0.010664:0.011806:0.018447:0.011759:0.011901:0.012020:0.006570:0.012949:0.018447:0.011211:0.011116:0.011925:0.006570:0.013139:0.011901:0.011759:0.011925:0.005022:0.004856:0.010664:0.005951:0.006570:0.010664:0.010664:0.010664:0.010664:0.010426:0.011830:0.018495:0.010545:0.007950:0.006570
Rajarajeswaran :@0.428782:0.226507:0.577930:0.226507:0.577930:0.206444:0.428782:0.206444:0.013663:0.010664:0.005165:0.010545:0.007950:0.010664:0.005094:0.011211:0.010545:0.015948:0.010664:0.007855:0.010664:0.011949:0.006570
Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, :@0.096494:0.256585:0.908552:0.256585:0.908552:0.238564:0.096494:0.238564:0.008267:0.008702:0.004682:0.004682:0.006157:0.008702:0.008274:0.005388:0.011823:0.009557:0.008702:0.008231:0.009621:0.005345:0.010690:0.008295:0.009685:0.009578:0.009578:0.004276:0.005345:0.009578:0.004682:0.005409:0.015308:0.008637:0.009578:0.004276:0.008295:0.004276:0.009493:0.008702:0.005388:0.008231:0.009706:0.009578:0.005345:0.011844:0.008702:0.008231:0.004276:0.004725:0.009557:0.005388:0.010690:0.008295:0.004276:0.008659:0.009557:0.008295:0.008659:0.008253:0.004682:0.005580:0.015308:0.009493:0.009557:0.008231:0.008253:0.009621:0.005345:0.011866:0.009557:0.004276:0.008231:0.008766:0.006072:0.008253:0.004276:0.004725:0.008274:0.005388:0.015308:0.008231:0.004276:0.008231:0.008274:0.008253:0.004276:0.008231:0.004746:0.005388:0.008231:0.008274:0.004126:0.008231:0.009621:0.005345:0.009471:0.008231:0.009557:0.009578:0.009578:0.009493:0.005388:0.010690:0.008702:0.004276:0.008231:0.004725:0.008231:0.009621:0.004682:0.005345
Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia :@0.291382:0.276339:0.713963:0.276339:0.713963:0.258318:0.291382:0.258318:0.010626:0.008317:0.009557:0.009578:0.008231:0.006115:0.005388:0.010690:0.009599:0.009493:0.012015:0.008231:0.008274:0.004682:0.005409:0.010690:0.008702:0.004276:0.008231:0.009621:0.009557:0.009514:0.006072:0.005452:0.011780:0.008295:0.006072:0.009599:0.004148:0.005388:0.009578:0.009514:0.008253:0.008231:0.009621:0.005345:0.009578:0.009578:0.009578:0.009578:0.009493:0.004682:0.005409:0.015308:0.008231:0.004276:0.008231:0.008274:0.008253:0.004276:0.008350:0.005345
*Corresponding Author: reyhaneh.farghadani@monash.edu :@0.276416:0.306071:0.729072:0.306071:0.729072:0.288050:0.276416:0.288050:0.008188:0.011823:0.009493:0.006072:0.006157:0.008702:0.008253:0.009578:0.009578:0.009514:0.009578:0.004361:0.009557:0.009557:0.005345:0.010733:0.009599:0.004661:0.009535:0.009578:0.006072:0.004682:0.005452:0.006072:0.008766:0.008274:0.009535:0.008231:0.009621:0.008659:0.009557:0.004682:0.004682:0.008295:0.006072:0.009557:0.009621:0.008231:0.009578:0.008231:0.009621:0.004276:0.017061:0.014367:0.009706:0.009557:0.008231:0.008253:0.009621:0.004810:0.008702:0.009578:0.009797:0.005345
Triple-negative  breast  cancer  (TNBC)  is  an  aggressive  subtype  of  breast  cancer :@0.171085:0.347954:0.920166:0.347954:0.920166:0.327892:0.171085:0.327892:0.010640:0.006760:0.004761:0.010664:0.004665:0.009689:0.007982:0.010711:0.009664:0.010640:0.009164:0.005189:0.004665:0.009164:0.009640:0.005951:0.008426:0.010664:0.006760:0.009664:0.009164:0.009188:0.005189:0.005951:0.008259:0.009236:0.009164:0.010711:0.009236:0.009688:0.006760:0.005951:0.008212:0.006689:0.010640:0.013139:0.011830:0.013163:0.006689:0.005951:0.008283:0.004761:0.009188:0.005951:0.008307:0.009164:0.010711:0.005951:0.008212:0.009164:0.010640:0.010640:0.006760:0.009759:0.009045:0.009236:0.004761:0.009069:0.009759:0.005951:0.008212:0.009236:0.010687:0.010664:0.005189:0.009093:0.010664:0.009759:0.005951:0.008236:0.010664:0.005284:0.005951:0.008283:0.010664:0.006760:0.009664:0.009164:0.009188:0.005189:0.005951:0.008259:0.009117:0.009164:0.010711:0.009236:0.009759:0.006855:0.005951
characterized by high recurrence rates and poor prognosis, often leading to distant metastases in :@0.085519:0.371337:0.919995:0.371337:0.919995:0.351274:0.085519:0.351274:0.009236:0.010711:0.009164:0.006665:0.009164:0.009236:0.005189:0.009616:0.006760:0.004642:0.008069:0.009759:0.010664:0.007545:0.010664:0.009259:0.007379:0.010711:0.004689:0.010640:0.010711:0.007569:0.006760:0.009640:0.009236:0.010687:0.006760:0.006665:0.009759:0.010616:0.009236:0.009759:0.007498:0.006760:0.009069:0.005189:0.009640:0.009236:0.007522:0.009164:0.010711:0.010664:0.007498:0.010664:0.010568:0.010664:0.006760:0.007498:0.010545:0.006760:0.010664:0.010640:0.010711:0.010545:0.009236:0.004761:0.009069:0.005213:0.007593:0.010545:0.005213:0.005189:0.009759:0.010616:0.007522:0.004761:0.009640:0.009164:0.010664:0.004689:0.010711:0.010640:0.007569:0.005189:0.010664:0.007498:0.010664:0.004594:0.009236:0.005189:0.009069:0.010711:0.005118:0.007522:0.015995:0.009664:0.005189:0.009069:0.009236:0.005189:0.009069:0.009236:0.009759:0.009188:0.007545:0.004761:0.010497:0.005951
the brain, lung, bone, and liver. Current chemotherapeutic regimens for TNBC are limited by drug :@0.085519:0.394719:0.920412:0.394719:0.920412:0.374656:0.085519:0.374656:0.005189:0.010640:0.009759:0.006903:0.010664:0.006760:0.009093:0.004761:0.010640:0.005213:0.007022:0.004761:0.010687:0.010640:0.010640:0.005308:0.006808:0.010664:0.010664:0.010711:0.009759:0.005213:0.006974:0.009164:0.010711:0.010473:0.006950:0.004761:0.004642:0.009164:0.009640:0.006760:0.005213:0.006950:0.013163:0.010687:0.006641:0.006760:0.009640:0.010711:0.005118:0.006950:0.009236:0.010711:0.009759:0.015900:0.010664:0.005189:0.010783:0.009759:0.006641:0.009164:0.010664:0.009688:0.010687:0.005189:0.004642:0.009236:0.006998:0.006760:0.009640:0.010640:0.004761:0.015995:0.009759:0.010711:0.009259:0.006808:0.005213:0.010735:0.006760:0.006903:0.010640:0.013020:0.011830:0.013163:0.006903:0.009164:0.007105:0.009759:0.006903:0.004761:0.004642:0.015995:0.004665:0.005260:0.009759:0.010664:0.006927:0.010664:0.009259:0.006950:0.010664:0.006760:0.010521:0.010545:0.005951
resistance and adverse side effects, underscoring the urgent need for novel and more effective :@0.085519:0.418135:0.919971:0.418135:0.919971:0.398072:0.085519:0.398072:0.006760:0.009640:0.009236:0.004761:0.009188:0.005189:0.009093:0.010711:0.009236:0.009759:0.009045:0.009164:0.010711:0.010664:0.009069:0.009164:0.010664:0.009164:0.009640:0.006760:0.009188:0.009759:0.009045:0.009236:0.004761:0.010664:0.009664:0.009093:0.009759:0.005213:0.005213:0.009593:0.009236:0.005189:0.009188:0.005308:0.009093:0.010687:0.010545:0.010664:0.009759:0.006665:0.009236:0.009236:0.010664:0.006760:0.004761:0.010473:0.010640:0.009140:0.005189:0.010640:0.009759:0.009021:0.010687:0.006760:0.010640:0.009688:0.010711:0.005118:0.009093:0.010711:0.009664:0.009759:0.010664:0.009069:0.005213:0.010735:0.006760:0.009045:0.010711:0.010664:0.009164:0.009664:0.004761:0.009045:0.009164:0.010711:0.010473:0.009093:0.015995:0.010664:0.006760:0.009616:0.009093:0.009759:0.005213:0.005213:0.009759:0.009236:0.005189:0.004665:0.009164:0.009759:0.005951
treatments. Reactive oxygen species (ROS) play a dual role in cancer, acting as a double-edged :@0.085519:0.441417:0.920582:0.441417:0.920582:0.421354:0.085519:0.421354:0.005189:0.006641:0.009759:0.009164:0.005189:0.015995:0.009640:0.010711:0.005118:0.009236:0.005213:0.008307:0.012163:0.009640:0.009164:0.009236:0.005237:0.004761:0.009069:0.009759:0.008164:0.010664:0.009545:0.009212:0.010711:0.009759:0.010616:0.008236:0.009188:0.010664:0.009664:0.009236:0.004761:0.009664:0.009236:0.008236:0.006689:0.012163:0.013139:0.011901:0.006689:0.008259:0.010664:0.004761:0.009093:0.009212:0.008307:0.009164:0.008069:0.010664:0.010687:0.009164:0.004761:0.008164:0.006760:0.010664:0.004665:0.009759:0.008164:0.004761:0.010640:0.008236:0.009236:0.009164:0.010711:0.009355:0.009759:0.006641:0.005213:0.008307:0.009164:0.009236:0.005189:0.004642:0.010711:0.010640:0.008283:0.009164:0.009188:0.008283:0.009164:0.008212:0.010664:0.010664:0.010687:0.010711:0.004761:0.010266:0.007982:0.009759:0.010664:0.010640:0.009569:0.010545:0.005951
sword. While modest ROS levels promote tumour progression, excessive ROS levels can suppress :@0.085519:0.464799:0.920329:0.464799:0.920329:0.444736:0.085519:0.444736:0.009236:0.013377:0.010664:0.006760:0.010545:0.005213:0.006450:0.017114:0.010711:0.004665:0.004761:0.009640:0.006379:0.015995:0.010521:0.010664:0.009759:0.009188:0.005189:0.006379:0.012163:0.013068:0.011901:0.006450:0.004761:0.009640:0.009164:0.009640:0.004761:0.009188:0.006403:0.010664:0.006760:0.010664:0.015995:0.010664:0.005118:0.009759:0.006331:0.005189:0.010687:0.015900:0.010664:0.010687:0.006760:0.006355:0.010664:0.007022:0.010664:0.010687:0.006760:0.009640:0.009188:0.009188:0.004761:0.010664:0.010711:0.005213:0.006403:0.009545:0.009521:0.009117:0.009759:0.009188:0.009259:0.004761:0.009069:0.009759:0.006331:0.012163:0.013068:0.011901:0.006450:0.004761:0.009640:0.009164:0.009640:0.004761:0.009188:0.006403:0.009236:0.009164:0.010711:0.006212:0.009236:0.010687:0.010664:0.010664:0.006760:0.009545:0.009236:0.009188:0.005951
tumours. Cancer cells with elevated ROS are highly dependent on antioxidant defences, and further :@0.085519:0.488181:0.919995:0.488181:0.919995:0.468119:0.085519:0.468119:0.005189:0.010687:0.015900:0.010664:0.010687:0.006760:0.009188:0.005213:0.006070:0.013163:0.009069:0.010711:0.009236:0.009759:0.006641:0.006093:0.009236:0.009759:0.004665:0.004761:0.009188:0.006117:0.013377:0.004761:0.005094:0.010711:0.006093:0.009759:0.004642:0.009759:0.009045:0.009164:0.005094:0.009807:0.010664:0.006141:0.012163:0.013068:0.011901:0.006022:0.009164:0.006665:0.009759:0.006046:0.010711:0.004689:0.010640:0.010711:0.004761:0.009093:0.006093:0.010664:0.009759:0.010664:0.009688:0.010711:0.010664:0.009759:0.010616:0.005189:0.006046:0.010664:0.010568:0.006093:0.009164:0.010711:0.005070:0.004761:0.010664:0.009474:0.004761:0.010664:0.009164:0.010711:0.005094:0.006093:0.010664:0.009759:0.005213:0.009759:0.010711:0.009045:0.009759:0.009188:0.005213:0.006165:0.009164:0.010711:0.010473:0.006093:0.005141:0.010687:0.006760:0.005070:0.010711:0.009664:0.006808:0.005951
increases in ROS levels beyond a tolerable threshold can induce cell death. Therefore, strategies that :@0.085519:0.511564:0.920424:0.511564:0.920424:0.491501:0.085519:0.491501:0.004761:0.010640:0.009236:0.006760:0.009664:0.009164:0.009188:0.009759:0.009188:0.005165:0.004761:0.010640:0.005141:0.012163:0.013068:0.011901:0.005213:0.004761:0.009640:0.009164:0.009759:0.004761:0.009188:0.005189:0.010664:0.009759:0.009212:0.010664:0.010711:0.010664:0.005165:0.009164:0.005094:0.005189:0.010664:0.004665:0.009759:0.006641:0.009164:0.010664:0.004689:0.009759:0.005213:0.005189:0.010640:0.006760:0.009640:0.009236:0.010711:0.010664:0.004761:0.010664:0.005094:0.009236:0.009164:0.010711:0.005094:0.004761:0.010640:0.010664:0.010687:0.009236:0.009759:0.005118:0.009236:0.009759:0.004665:0.004761:0.005070:0.010664:0.009759:0.009093:0.005189:0.010640:0.005213:0.005189:0.010640:0.010711:0.009759:0.006665:0.009759:0.005213:0.010664:0.006760:0.009640:0.005141:0.005141:0.009236:0.005189:0.006641:0.009164:0.005094:0.009759:0.010640:0.004689:0.009759:0.009188:0.005141:0.005189:0.010640:0.009236:0.005260:0.005951
elevate ROS levels are being explored to preferentially induce cell death in cancer cells, contributing :@0.085519:0.534946:0.920438:0.534946:0.920438:0.514883:0.085519:0.514883:0.009759:0.004642:0.009759:0.009045:0.009236:0.005189:0.009640:0.005570:0.012163:0.013130:0.011901:0.005641:0.004761:0.009640:0.009164:0.009759:0.004856:0.009236:0.005570:0.009164:0.006665:0.009759:0.005498:0.010664:0.009759:0.004665:0.010711:0.010640:0.005594:0.009759:0.009474:0.010664:0.004761:0.010521:0.006760:0.009640:0.010664:0.005594:0.005189:0.010664:0.005522:0.010664:0.006760:0.009664:0.005213:0.009759:0.006760:0.009616:0.010711:0.005118:0.004761:0.009164:0.004761:0.004761:0.009212:0.005546:0.004761:0.010640:0.010664:0.010687:0.009236:0.009759:0.005546:0.009236:0.009759:0.004665:0.004761:0.005498:0.010664:0.009759:0.009093:0.005189:0.010640:0.005570:0.004761:0.010640:0.005570:0.009236:0.009164:0.010711:0.009236:0.009688:0.006760:0.005498:0.009236:0.009759:0.004665:0.004832:0.009236:0.005213:0.005475:0.009236:0.010664:0.010711:0.005189:0.006665:0.004761:0.010664:0.010687:0.005094:0.004761:0.010640:0.010640:0.005951
to the efficacy of many anticancer agents. Schiff bases, biologically active molecules with enhanced :@0.085519:0.558228:0.920019:0.558228:0.920019:0.538165:0.085519:0.538165:0.005189:0.010664:0.006212:0.005189:0.010640:0.009759:0.006189:0.009759:0.005213:0.005213:0.004761:0.009236:0.009164:0.009117:0.009212:0.006165:0.010664:0.005213:0.006046:0.015995:0.009093:0.010711:0.009212:0.006284:0.009164:0.010711:0.005070:0.004761:0.009236:0.009164:0.010616:0.009236:0.009759:0.006665:0.006236:0.009164:0.010640:0.009759:0.010640:0.005189:0.009188:0.005260:0.006093:0.011901:0.009307:0.010711:0.004546:0.005213:0.005213:0.006236:0.010664:0.008998:0.009236:0.009759:0.009045:0.005213:0.006308:0.010664:0.004761:0.010664:0.004761:0.010497:0.010640:0.004761:0.009236:0.009164:0.004689:0.004761:0.009212:0.006093:0.009164:0.009236:0.005189:0.004642:0.009164:0.009640:0.006236:0.015995:0.010664:0.004761:0.009640:0.009236:0.010687:0.004761:0.009664:0.009236:0.006236:0.013377:0.004761:0.005094:0.010711:0.006236:0.009759:0.010616:0.010711:0.009164:0.010616:0.009236:0.009759:0.010664:0.005951
pharmacological activities, have shown significant promise in drug discovery. Recent efforts have :@0.085519:0.581610:0.920345:0.581610:0.920345:0.561547:0.085519:0.561547:0.010664:0.010711:0.009164:0.006665:0.015995:0.009093:0.009236:0.010664:0.004761:0.010664:0.010687:0.004761:0.009236:0.009164:0.004642:0.007664:0.009164:0.009236:0.005189:0.004642:0.009164:0.004665:0.005260:0.004761:0.009640:0.009236:0.005213:0.007879:0.010711:0.009164:0.009069:0.009759:0.007760:0.009188:0.010616:0.010664:0.013377:0.010711:0.007688:0.009236:0.004761:0.010640:0.010711:0.004665:0.005213:0.004761:0.009236:0.009164:0.010711:0.005094:0.007664:0.010664:0.006760:0.010664:0.015995:0.004665:0.009236:0.009759:0.007760:0.004761:0.010981:0.007839:0.010664:0.006760:0.010687:0.010521:0.007664:0.010664:0.004761:0.009188:0.009283:0.010664:0.009164:0.009688:0.006760:0.009069:0.005213:0.007879:0.012163:0.009640:0.009236:0.009759:0.010521:0.005189:0.007760:0.009759:0.005213:0.005213:0.010711:0.006760:0.005070:0.009236:0.007807:0.010711:0.009164:0.009069:0.009807:0.005951
focused on developing Schiff base derivatives with potent anticancer properties and reduced toxicity. :@0.085519:0.604993:0.920281:0.604993:0.920281:0.584930:0.085519:0.584930:0.005213:0.010735:0.009236:0.010568:0.009236:0.009759:0.010664:0.004951:0.010664:0.010711:0.005141:0.010664:0.009759:0.009093:0.009759:0.004642:0.010664:0.010664:0.004761:0.010711:0.010640:0.005022:0.011901:0.009307:0.010711:0.004689:0.005141:0.005213:0.005189:0.010664:0.008998:0.009236:0.009545:0.005141:0.010664:0.009759:0.006665:0.004761:0.009069:0.009164:0.005094:0.004832:0.009164:0.009640:0.009236:0.005141:0.013377:0.004761:0.005094:0.010711:0.005118:0.010664:0.010664:0.005189:0.009688:0.010711:0.005118:0.005141:0.009164:0.010711:0.005070:0.004761:0.009236:0.009164:0.010616:0.009236:0.009759:0.006760:0.005165:0.010664:0.006760:0.010664:0.010664:0.009759:0.006641:0.005189:0.004642:0.009759:0.009188:0.005141:0.009164:0.010711:0.010664:0.005094:0.006760:0.009640:0.010664:0.010687:0.009236:0.009759:0.010664:0.005141:0.005189:0.010664:0.009474:0.004761:0.009236:0.004761:0.005094:0.009117:0.005213:0.005951
In this study, we investigated the anticancer potential of a novel β:@0.085519:0.628375:0.635576:0.628375:0.635576:0.608312:0.085519:0.608312:0.005332:0.010640:0.006522:0.005189:0.010640:0.004761:0.009188:0.006403:0.009236:0.005189:0.010687:0.010664:0.009093:0.005141:0.006522:0.013377:0.009569:0.006379:0.004761:0.010640:0.009164:0.009640:0.009236:0.005189:0.004642:0.010640:0.009164:0.005189:0.009640:0.010664:0.006570:0.005189:0.010640:0.009759:0.006474:0.009164:0.010711:0.005070:0.004761:0.009236:0.009164:0.010616:0.009236:0.009759:0.006665:0.006522:0.010664:0.010664:0.005189:0.009688:0.010711:0.005118:0.004761:0.009069:0.004761:0.006474:0.010664:0.005213:0.006474:0.009164:0.006498:0.010545:0.010664:0.009164:0.009688:0.004761:0.006474:0.011021
-diiminato Schiff base compound :@0.635927:0.628375:0.920425:0.628375:0.920425:0.608312:0.635927:0.608312:0.007982:0.010545:0.004761:0.004642:0.015995:0.004665:0.010711:0.009164:0.005070:0.010664:0.006570:0.011901:0.009307:0.010711:0.004689:0.005141:0.005213:0.006450:0.010664:0.009164:0.009188:0.009759:0.006522:0.009117:0.010664:0.015995:0.010664:0.010568:0.010687:0.010711:0.010664:0.005951
in TNBC, focusing on its ability to induce ROS generation. Our findings demonstrate that the Schiff :@0.085519:0.651757:0.920033:0.651757:0.920033:0.631695:0.085519:0.631695:0.004761:0.010640:0.006379:0.010640:0.013139:0.011830:0.013163:0.005213:0.006284:0.005213:0.010664:0.009236:0.010687:0.009188:0.004761:0.010545:0.010786:0.006414:0.010664:0.010568:0.006379:0.004761:0.005070:0.009236:0.006379:0.009164:0.010664:0.004689:0.004761:0.004642:0.005189:0.009212:0.006379:0.005189:0.010664:0.006355:0.004761:0.010640:0.010664:0.010687:0.009236:0.009759:0.006379:0.012163:0.013068:0.011901:0.006308:0.010640:0.009759:0.010521:0.009759:0.006641:0.009164:0.005094:0.004761:0.010664:0.010711:0.005213:0.006403:0.013139:0.010687:0.006665:0.006379:0.005213:0.004761:0.010711:0.010664:0.004761:0.010711:0.010640:0.009188:0.006308:0.010664:0.009759:0.015924:0.010664:0.010568:0.009236:0.005189:0.006641:0.009164:0.005094:0.009807:0.006379:0.005189:0.010640:0.009164:0.005094:0.006379:0.005189:0.010640:0.009759:0.006331:0.011901:0.009307:0.010711:0.004689:0.005213:0.005046:0.005951
base derivative significantly elevates intracellular ROS levels in TNBC cells in a dose-dependent :@0.085519:0.675140:0.920512:0.675140:0.920512:0.655077:0.085519:0.655077:0.010664:0.009164:0.009188:0.009759:0.008664:0.010664:0.009759:0.006665:0.004761:0.009069:0.009164:0.005094:0.004761:0.009069:0.009759:0.008593:0.009236:0.004761:0.010640:0.010711:0.004665:0.005213:0.004761:0.009236:0.009164:0.010711:0.005094:0.004761:0.009212:0.008664:0.009759:0.004642:0.009759:0.009045:0.009164:0.005189:0.009759:0.009188:0.008712:0.004761:0.010640:0.005189:0.006641:0.009164:0.009236:0.009688:0.004761:0.004642:0.010687:0.004761:0.009164:0.006760:0.008664:0.012163:0.013068:0.011901:0.008736:0.004761:0.009640:0.009164:0.009640:0.004761:0.009188:0.008688:0.004761:0.010640:0.008664:0.010640:0.013020:0.011830:0.013163:0.008616:0.009236:0.009759:0.004665:0.004761:0.009188:0.008688:0.004761:0.010640:0.008664:0.009164:0.008640:0.010545:0.010545:0.009236:0.010149:0.007982:0.010664:0.009759:0.010664:0.009688:0.010711:0.010664:0.009759:0.010616:0.005260:0.005951
manner, as measured by DCFDA assay. This increase in ROS disrupts mitochondrial membrane :@0.085519:0.698455:0.920439:0.698455:0.920439:0.678392:0.085519:0.678392:0.015995:0.009093:0.010711:0.010711:0.009640:0.006760:0.005213:0.008521:0.009164:0.009069:0.008521:0.015995:0.009664:0.009164:0.009188:0.010687:0.006760:0.009664:0.010664:0.008545:0.010545:0.009117:0.008521:0.013115:0.013163:0.010664:0.012949:0.011901:0.008450:0.009164:0.009069:0.009236:0.009164:0.009212:0.005213:0.008307:0.010640:0.010711:0.004761:0.009093:0.008521:0.004761:0.010640:0.009236:0.006760:0.009664:0.009164:0.009188:0.009759:0.008497:0.004761:0.010640:0.008521:0.012163:0.013068:0.011901:0.008450:0.010664:0.004594:0.009188:0.006641:0.010687:0.010664:0.005189:0.009188:0.008569:0.015995:0.004665:0.005189:0.010664:0.009236:0.010711:0.010664:0.010545:0.011012:0.006760:0.004642:0.009164:0.004665:0.008521:0.015995:0.009664:0.015995:0.010664:0.006760:0.009045:0.010806:0.009807:0.005951
integrity, activating the intrinsic apoptotic pathway. In vivo studies also confirmed the safety profile :@0.085519:0.721837:0.919995:0.721837:0.919995:0.701775:0.085519:0.701775:0.004761:0.010640:0.005189:0.009640:0.010640:0.006760:0.004761:0.005070:0.009212:0.005308:0.006665:0.009164:0.009236:0.005189:0.004642:0.009164:0.009164:0.005189:0.004832:0.010711:0.010640:0.006712:0.005189:0.010640:0.009759:0.006617:0.004761:0.010640:0.005189:0.006641:0.004761:0.010640:0.009236:0.004761:0.009236:0.006641:0.009236:0.010664:0.010664:0.010711:0.005189:0.010664:0.005094:0.004761:0.009236:0.006641:0.010664:0.009164:0.005118:0.010711:0.013377:0.009164:0.009069:0.005213:0.006736:0.005332:0.010640:0.006665:0.009164:0.004665:0.009164:0.010664:0.006665:0.009236:0.005189:0.010687:0.010664:0.004665:0.009759:0.009188:0.006546:0.009164:0.004665:0.009236:0.010664:0.006712:0.009236:0.010664:0.010592:0.005213:0.004761:0.006760:0.015900:0.009759:0.010664:0.006641:0.005189:0.010640:0.009759:0.006617:0.009236:0.009164:0.005213:0.009759:0.005094:0.009212:0.006736:0.010664:0.006760:0.010521:0.005213:0.004761:0.004761:0.009640:0.005951
of the compound. These results suggest that ROS generation is a critical mechanism underlying the :@0.085519:0.745220:0.920328:0.745220:0.920328:0.725157:0.085519:0.725157:0.010664:0.005284:0.005855:0.005189:0.010640:0.009759:0.005784:0.009117:0.010664:0.015995:0.010664:0.010664:0.010687:0.010592:0.010545:0.005213:0.005951:0.010640:0.010711:0.009521:0.009236:0.009759:0.005784:0.006760:0.009640:0.009236:0.010687:0.004761:0.005070:0.009236:0.005713:0.009188:0.010687:0.010640:0.010640:0.009759:0.009188:0.005189:0.005832:0.005189:0.010640:0.009164:0.005094:0.005855:0.012163:0.013068:0.011901:0.005641:0.010640:0.009759:0.010711:0.009664:0.006760:0.009069:0.005189:0.004642:0.010664:0.010711:0.005855:0.004761:0.009188:0.005855:0.009164:0.005808:0.009236:0.006760:0.004665:0.005189:0.004642:0.009236:0.009164:0.004761:0.005784:0.015995:0.009664:0.009236:0.010711:0.009164:0.010711:0.004642:0.009236:0.015995:0.005808:0.010687:0.010711:0.010664:0.009759:0.006641:0.004761:0.009212:0.004761:0.010640:0.010640:0.005951:0.005070:0.010711:0.009759:0.005951
anticancer  activity  of  Schiff  base  derivatives,  offering  a  promising  avenue  for  developing  new :@0.085519:0.768602:0.920148:0.768602:0.920148:0.748539:0.085519:0.748539:0.009164:0.010711:0.005070:0.004761:0.009236:0.009164:0.010616:0.009236:0.009759:0.006665:0.005951:0.004856:0.009164:0.009236:0.005189:0.004642:0.009236:0.004761:0.005189:0.009259:0.005951:0.004856:0.010545:0.005213:0.005951:0.004784:0.011901:0.009307:0.010711:0.004689:0.005141:0.005213:0.005951:0.004927:0.010664:0.008998:0.009236:0.009759:0.005951:0.004784:0.010664:0.009759:0.006665:0.004961:0.009164:0.009069:0.005189:0.004761:0.009164:0.009688:0.009236:0.005213:0.005951:0.004927:0.010545:0.005213:0.005308:0.009545:0.006760:0.004642:0.010711:0.010640:0.005951:0.004880:0.009164:0.005951:0.004808:0.010664:0.006760:0.010664:0.015995:0.004665:0.009236:0.004761:0.010497:0.010640:0.005951:0.004903:0.009164:0.009069:0.009759:0.010616:0.010687:0.009759:0.005951:0.004784:0.005213:0.010735:0.006760:0.005951:0.004808:0.010664:0.009569:0.009164:0.009640:0.004761:0.010664:0.010664:0.004761:0.010640:0.010640:0.005951:0.004903:0.010711:0.009664:0.013377:0.005951
therapeutic strategies against TNBC. :@0.085519:0.791984:0.393113:0.791984:0.393113:0.771922:0.085519:0.771922:0.005189:0.010640:0.009759:0.006641:0.009164:0.010664:0.009688:0.010687:0.005260:0.004761:0.009236:0.005951:0.009259:0.005189:0.006641:0.009164:0.005094:0.009807:0.010640:0.004761:0.009688:0.009236:0.005951:0.009164:0.010640:0.009164:0.004761:0.010640:0.009236:0.005189:0.005784:0.010640:0.013139:0.011711:0.013163:0.005347:0.005951
 :@0.085519:0.815266:0.092136:0.815266:0.092136:0.796499:0.085519:0.796499:0.006617